30 years to 80 years
Male or Female
Stroke is one of the top causes of death and major functional disability worldwide. Treatment options for acute ischemic stroke are limited and primarily focus on timely clot removal to restore circulation. A small proportion of patients are eligible for tissue plasminogen activator (tPA) and/or thrombectomy. However, treatment response is incomplete for many patients, and even patients who respond to treatment may have residual neurologic impairment.Elezanumab is an investigational product under development for improvement of neurologic function in patients with acute ischemic stroke. A novel treatment like elezanumab, with a potentially neurorestorative mechanism of action, may improve neurologic function, and represents a significant advance in available treatment options for patients suffering from acute ischemic stroke.
For further information about this study or to express your interest in this study, please fill out and submit this form.
This setting allows you to view available services and providers associated with your preferred location. You can change this setting at any time.
Cookies are required to view location specific content.
We’ve developed a new tool on our website allowing you to see content most relevant to you and your preferred location. It’s our way of making the information you need, more personalized.
You’ll find this feature labeled “Set My Location” throughout the website. Most often, you’ll see it in the top left corner of every page.
You’ll also find a feature that allows you to set your location temporarily, as seen below.